Ticker Hub
RAPP — AI Analysis & Sentiment
5 recent AI-generated analyses for RAPP. Sentiment and confidence insights updated continuously.
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics delivered positive Q1 2026 results driven by a new strategic partnership and reinforcing clinical data for its lead candidate....
May 7, 2026Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics reported robust follow-up Phase 2a results for RAP-219, its lead drug for focal onset seizures. This positive data significant...
Apr 21, 2026Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rapport Therapeutics delivered strong clinical trial results for its lead epilepsy drug, secured a significant partnership, and extended its cash r...
Mar 10, 2026Rapport Therapeutics与Tenacia Biotechnology宣布达成大中华区RAP-219开发与商业化战略合作
Rapport Therapeutics' partnership with Tenacia Biotechnology for RAP-219 in Greater China provides significant funding and market access for its le...
Mar 9, 2026Rapport Therapeutics与Tenacia Biotechnology宣布达成大中华区RAP-219开发与商业化战略合作
Rapport Therapeutics' partnership with Tenacia for RAP-219 in Greater China provides significant non-dilutive capital and expands market potential,...
Mar 9, 2026